InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. Our mission is to develop and facilitate market entry for novel products worldwide that preserve and improve vision.
Our lead product, AzaSite® (azithromycin ophthalmic solution) 1%, is approved by the United States Food and Drug Administration (FDA) and the Therapeutic Products Directorate (TPD) of Health Canada for the treatment of bacterial conjunctivitis. AzaSite is formulated with our proprietary DuraSite® technology, which extends the residence time of the antibiotic azithromycin on the eye for several hours, thereby reducing the need for the frequent dosing regimen related to conventional anti-infective eye drops. AzaSite was launched in the U.S. in August 2007 by Inspire Pharmaceuticals, InSite’s commercial partner for the U.S. and Canada and will be marketed by international partners in Japan, Europe, South Korea, select countries in South America, Turkey and China upon approval in those countries. InSite will also pursue partnerships with companies who share our commitment to bringing innovative ophthalmic products such as AzaSite to patients worldwide.
AzaSite Plus (ISV-502), another product candidate in the AzaSite family, is currently in late-stage development for the treatment of eyelid infection and inflammation, specifically for the indication of blepharitis.
Our strategy includes maximizing AzaSite sales in the U.S. and abroad through close collaboration with marketing partners, seeking development partners for our DuraSite-enabled early-stage product candidates, and applying our expertise in ophthalmology to identify, in-license, or acquire promising new product candidates or technologies.
Commercial partnerships: InSite Vision receives royalty payments from our two commercial products, AzaSite® (azithromycin ophthalmic solution) 1% and Besivance™ (besifloxacin ophthalmic suspension) 0.6%. AzaSite is approved in the United States and Canada and marketed by InSite Vision’s partner, Inspire Pharmaceuticals. InSite Vision has also formed multiple strategic licensing and distribution agreements with partners to market AzaSite in select countries in Europe, Asia and South America upon regulatory approval in those regions. Besivance was approved by the U.S. Food and Drug Administration in 2009 and is being commercialized by Bausch & Lomb and Pfizer Inc. We work closely with our partners to support and extend product sales.
Authorized Shares (AS) = 240 million
Outstanding Shares (OS) = 94.74 million
Restricted Shares = 21.73 million
Float = 73.01 million
INSV SEC Filings
· Louis Drapeau
Chief Executive Officer, Vice President and Chief Financial Officer
· Lyle M. Bowman, Ph.D.
Vice President, Development
· David Heniges
Vice President and General Manager, Commercial Opportunities
· Kamran Hosseini, M.D., Ph.D.
Vice President, Clinical Affairs and Chief Medical Officer
· Surendra Patel
Vice President, Operations and Quality
INSV Contact Information
Insite Vision Inc.
965 Atlantic Avenue
Alameda, CA 94501
United States - Map
Web Site: http://www.insitevision.com